INDIANAPOLIS, June 11, 2021 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) will host a webcast on Thursday, July 1, 2021 to discuss the company's
diabetes portfolio and its presentations at the American Diabetes
Association's Virtual 81st Scientific Sessions. The webcast will
begin at 10:00 a.m. Eastern Time and
remarks will focus on results from the tirzepatide SURPASS clinical
trial program and expected next steps for tirzepatide, as well as
Lilly's once-weekly basal insulin and early-phase incretins in
people with diabetes.
Investors, media and the general public can access a live
webcast of the conference call through a link that will be posted
on Lilly's website at
https://investor.lilly.com/webcasts-and-presentations. A replay
will also be available on the website following the conference
call.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with
discovery to create medicines that make life better for people
around the world. We were founded more than a century ago by a man
committed to creating high-quality medicines that meet real needs,
and today we remain true to that mission in all our work. Across
the globe, Lilly employees work to discover and bring life-changing
medicines to those who need them, improve the understanding and
management of disease, and give back to communities through
philanthropy and volunteerism. To learn more about Lilly,
please visit us at www.lilly.com and www.lilly.com/news. F-LLY
Lilly Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements (as
that term is defined in the Private Securities Litigation Reform
Act of 1995) about tirzepatide as well as Lilly's once-weekly basal
insulin and early-phase incretins and reflects Lilly's current
beliefs and expectations. However, as with any pharmaceutical
product, there are substantial risks and uncertainties in the
process of research, development, and commercialization. Among
other things, there can be no guarantee that the studies will be
completed as planned, that future study results will be consistent
with the results to date or that medicines will receive regulatory
approvals or be commercially successful. For a further discussion
of these and other risks and uncertainties, please see Lilly's most
recent Form 10-K and Form 10-Q filings with the U.S. Securities and
Exchange Commission. Except as required by law, Lilly undertakes no
duty to update forward-looking statements to reflect events after
the date of this release.
Refer to:
Molly McCully;
mccully_molly@lilly.com; 317-478-5423 (Media)
Kevin Hern; hern_kevin_r@lilly.com;
317-277-1838 (Investors)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lilly-announces-webcast-to-provide-diabetes-portfolio-update-at-ada-301310953.html
SOURCE Eli Lilly and Company